Skip to main content
Dryad logo

Data from: Assessment of tumor treatment response using active contrast encoding (ACE)-MRI: comparison with conventional DCE-MRI

Citation

Zhang, Jin et al. (2020), Data from: Assessment of tumor treatment response using active contrast encoding (ACE)-MRI: comparison with conventional DCE-MRI, Dryad, Dataset, https://doi.org/10.5061/dryad.8cz8w9gm9

Abstract

Purpose: To investigate the validity of contrast kinetic parameter estimates from Active Contrast Encoding (ACE)-MRI against those from conventional Dynamic Contrast-Enhanced (DCE)-MRI for evaluation of tumor treatment response in mouse tumor models.

Methods: The ACE-MRI method that incorporates measurement of T1 and B1 into the enhancement curve washout region, was implemented on a 7T  MRI scanner to measure tracer kinetic model  parameters of 4T1 and GL261 tumors with treatment using bevacizumab and 5FU. A portion of the same ACE-MRI data was used for conventional DCE-MRI data analysis with a separately measured pre-contrast T1 map. Tracer kinetic model  parameters, such as Ktrans (permeability area surface product) and ve (extracellular space volume fraction), estimated from ACE-MRI were compared with those from DCE-MRI, in terms of  correlation and Bland-Altman analyses. 

Results: A three-fold increase of the median Ktrans by treatment was observed in the flank 4T1 tumors by both ACE-MRI and DCE-MRI. In contrast, the brain tumors did not show a significant change by the treatment in either ACE-MRI or DCE-MRI. Ktrans and ve values  of the tumors from ACE-MRI were strongly correlated with those from DCE-MRI methods with correlation coefficients of 0.92 and 0.78, respectively, for the median values of 17 tumors. The Bland-Altman plot analysis showed a mean difference of -0.01 /min for Ktrans with the 95% limits of agreement of -0.12 /min to 0.09 /min, and -0.05 with -0.37 to 0.26 for ve.

Conclusion: The  tracer kinetic model parameters estimated from ACE-MRI and their changes by treatment closely matched those of DCE-MRI, which suggests that ACE-MRI can be used in place of conventional DCE-MRI for tumor progression monitoring and treatment response evaluation with a reduced scan time. 
 

Funding

National Institutes of Health, Award: 1S10OD018337-01